Therapeutic Gene Editing in Dyslipidemias

Area of Science:

• Genetics and Molecular Biology
• Cardiovascular Medicine
• Biotechnology

Background:

• Dyslipidemia significantly increases atherosclerotic cardiovascular disease risk.
• Current dyslipidemia treatments face challenges with long-term patient adherence.
• Novel, enduring therapeutic strategies for dyslipidemia are needed.

Purpose of the Study:

• To review gene editing tools for dyslipidemia management.
• To analyze pre-clinical and clinical studies on gene editing safety and efficacy.
• To explore therapeutic implications of targeting key lipid metabolism genes.

Main Methods:

• Comprehensive literature review of gene editing technologies (CRISPR/Cas9).
• Analysis of studies targeting genes like LDLR, PCSK9, ANGPTL3, APOC3, and Lp(a).
• Evaluation of safety, efficacy, and mechanistic insights of gene editing interventions.

Main Results:

• Gene editing demonstrates potential for sustained control of lipid homeostasis.
• Targeting specific genes involved in lipid metabolism shows promising outcomes.
• Pre-clinical and clinical data suggest feasibility of gene editing for dyslipidemia.

Conclusions:

• Gene editing, particularly CRISPR/Cas9, presents a groundbreaking approach for dyslipidemia.
• This technology offers potential for long-term management and cardiovascular risk reduction.
• Challenges and ethical considerations require careful navigation for future clinical translation.